Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials

BACKGROUND: The efficiency of capecitabine has been proven in early-stage triple negative breast cancer (eTNBC) with residue invasive tumor (non-pCR) after standard neoadjuvant chemotherapy (NACT). However, for those unselected eTNBC patients without screening from NACT (i.e., newly diagnosed eTNBC...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Feng, Bian, Lei, Wen, Jiahuai, Yu, Ping, Li, Na, Xie, Xiaoming, Wang, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917675/
https://www.ncbi.nlm.nih.gov/pubmed/35279130
http://dx.doi.org/10.1186/s12885-022-09326-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917675/
https://www.ncbi.nlm.nih.gov/pubmed/35279130
http://dx.doi.org/10.1186/s12885-022-09326-5

Ejemplares similares